| Hazard Information | Back Directory | [Description]
Isotonitazene-d7 (CRM) (Item No. 39682) is intended for use as an internal standard for the quantification of isotonitazene (Item Nos. 30880 | 27255) by GC- or LC-MS. Isotonitazene is categorized as an opioid.1,2,3 Isotonitazene has analgesic effects in mice.4 It has been associated with overdoses.5 Isotonitazene-d7 is regulated as a Schedule I compound in the United States. Isotonitazene-d7 (CRM) (Item No. 39682) is provided as a DEA exempt preparation. This product is intended for research and forensic applications.WARNING This product is not for human or veterinary use. | [Description]
Isotonitazene-d7 (Item No. 29319) is intended for use as an internal standard for the quantification of isotonitazene (Item Nos. 30880 | 27255) by GC- or LC-MS. Isotonitazene is categorized as an opioid.1,2,3 Isotonitazene has analgesic effects in mice.4 It has been associated with overdoses.5 Isotonitazene is regulated as a Schedule I compound in the United States. This product is intended for research and forensic applications.WARNING This product is not for human or veterinary use. | [References]
[1] A. F. CASY J. W. Ionisation constants and partition coefficients of some analgesically active 2-benzylbenzimidazole derivatives and related compounds[J]. Journal of Pharmacy and Pharmacology, 1966, 18 10: 677-683. DOI: 10.1111/j.2042-7158.1966.tb07782.x
[2] PETER BLANCKAERT. Report on a novel emerging class of highly potent benzimidazole NPS opioids: Chemical and in vitro functional characterization of isotonitazene[J]. Drug Testing and Analysis, 2019, 12 4: 422-430. DOI: 10.1002/dta.2738
[3] MARTHE M. VANDEPUTTE. Synthesis, Chemical Characterization, and μ-Opioid Receptor Activity Assessment of the Emerging Group of “Nitazene” 2-Benzylbenzimidazole Synthetic Opioids.[J]. ACS Chemical Neuroscience, 2021. DOI: 10.22541/au.160520665.59016513/v2
[4] ISTVÁN UJVÁRY*. DARK Classics in Chemical Neuroscience: Etonitazene and Related Benzimidazoles[J]. ACS Chemical Neuroscience, 2021, 12 7: 1072-1092. DOI: 10.1021/acschemneuro.1c00037
[5] CHELSEA L SHOVER. Emerging Characteristics of Isotonitazene-Involved Overdose Deaths: A Case-Control Study.[J]. Journal of Addiction Medicine, 2021, 15 5: 429-431. DOI: 10.1097/adm.0000000000000775
[6] ALEX J. KROTULSKI. Metonitazene in the United States—Forensic toxicology assessment of a potent new synthetic opioid using liquid chromatography mass spectrometry[J]. Drug Testing and Analysis, 2021, 13 10: 1697-1711. DOI: 10.1002/dta.3115 |
|
|